These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26126332)

  • 1. [Causative genetic variants of pseudohypoaldosteronism type II and essential hypertension].
    Mori T; Uchida S
    Nihon Jinzo Gakkai Shi; 2015; 57(4):751-7. PubMed ID: 26126332
    [No Abstract]   [Full Text] [Related]  

  • 2. Some assembly required: putting the epithelial sodium channel together.
    Butterworth MB; Weisz OA; Johnson JP
    J Biol Chem; 2008 Dec; 283(51):35305-9. PubMed ID: 18713729
    [No Abstract]   [Full Text] [Related]  

  • 3. [Severity of familial hyperkalemic hypertension caused by CUL-3 mutations: a story about kidneys and blood vessels].
    Rafael C; Hadchouel J
    Med Sci (Paris); 2020 May; 36(5):455-458. PubMed ID: 32452365
    [No Abstract]   [Full Text] [Related]  

  • 4. Pseudohypoaldosteronism Type II: A Young Girl Presented with Hypertension, Hyperkalemia and Metabolic Acidosis.
    Sethar GH; Almoghawi A; Khan N; Altourah W; Ashour NM
    J Coll Physicians Surg Pak; 2018 Mar; 28(3):S21-S22. PubMed ID: 29482694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudohypoaldosteronism type 2 presenting with hypertension and hyperkalaemia due to a novel mutation in the WNK4 gene.
    Brooks AM; Owens M; Sayer JA; Salzmann M; Ellard S; Vaidya B
    QJM; 2012 Aug; 105(8):791-4. PubMed ID: 21764813
    [No Abstract]   [Full Text] [Related]  

  • 6. Disorders of the epithelial Na(+) channel in Liddle's syndrome and autosomal recessive pseudohypoaldosteronism type 1.
    Oh YS; Warnock DG
    Exp Nephrol; 2000; 8(6):320-5. PubMed ID: 11014928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial sodium channel and its implication in the control of blood pressure.
    Hummler E
    Kidney Blood Press Res; 1998; 21(2-4):253-5. PubMed ID: 9762847
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of novel mutation of Cullin 3 gene in pseudohypoaldosteronism type II.
    Wang L; Nie M; Guo F; Tian Z; Guo X; Zhang S
    J Hypertens; 2022 Jun; 40(6):1239-1242. PubMed ID: 35703886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased chloride reabsorption as an inherited renal tubular defect in familial type II pseudohypoaldosteronism.
    Take C; Ikeda K; Kurasawa T; Kurokawa K
    N Engl J Med; 1991 Feb; 324(7):472-6. PubMed ID: 1988833
    [No Abstract]   [Full Text] [Related]  

  • 10. WNK4 is indispensable for the pathogenesis of pseudohypoaldosteronism type II caused by mutant KLHL3.
    Susa K; Sohara E; Takahashi D; Okado T; Rai T; Uchida S
    Biochem Biophys Res Commun; 2017 Sep; 491(3):727-732. PubMed ID: 28743496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inherited forms of mineralocorticoid hypertension.
    Hassan-Smith Z; Stewart PM
    Curr Opin Endocrinol Diabetes Obes; 2011 Jun; 18(3):177-85. PubMed ID: 21494136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudohypoaldosteronism type II: history, arguments, answers, and still some questions.
    Healy JK
    Hypertension; 2014 Apr; 63(4):648-54. PubMed ID: 24396028
    [No Abstract]   [Full Text] [Related]  

  • 13. Gordon's syndrome, renal tubule, chromosome 17 and essential hypertension: a credible link?
    Soubrier F
    J Hum Hypertens; 1998 Oct; 12(10):663-4. PubMed ID: 9819011
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular mechanisms of human hypertension.
    Lifton RP; Gharavi AG; Geller DS
    Cell; 2001 Feb; 104(4):545-56. PubMed ID: 11239411
    [No Abstract]   [Full Text] [Related]  

  • 15. Human hypertension caused by mutations in WNK kinases.
    Wilson FH; Disse-Nicodème S; Choate KA; Ishikawa K; Nelson-Williams C; Desitter I; Gunel M; Milford DV; Lipkin GW; Achard JM; Feely MP; Dussol B; Berland Y; Unwin RJ; Mayan H; Simon DB; Farfel Z; Jeunemaitre X; Lifton RP
    Science; 2001 Aug; 293(5532):1107-12. PubMed ID: 11498583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor mutations.
    Zennaro MC; Fernandes-Rosa F
    J Endocrinol; 2017 Jul; 234(1):T93-T106. PubMed ID: 28348114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21.
    Mansfield TA; Simon DB; Farfel Z; Bia M; Tucci JR; Lebel M; Gutkin M; Vialettes B; Christofilis MA; Kauppinen-Makelin R; Mayan H; Risch N; Lifton RP
    Nat Genet; 1997 Jun; 16(2):202-5. PubMed ID: 9171836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salt handling and hypertension.
    O'Shaughnessy KM; Karet FE
    Annu Rev Nutr; 2006; 26():343-65. PubMed ID: 16602929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudohypoaldosteronism: kidney, lungs and colon.
    Fuller PJ; Rogerson FM
    Clin Endocrinol (Oxf); 2002 May; 56(5):571-2. PubMed ID: 12030904
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
    Hiltunen TP; Donner KM; Sarin AP; Saarela J; Ripatti S; Chapman AB; Gums JG; Gong Y; Cooper-DeHoff RM; Frau F; Glorioso V; Zaninello R; Salvi E; Glorioso N; Boerwinkle E; Turner ST; Johnson JA; Kontula KK
    J Am Heart Assoc; 2015 Jan; 4(1):e001521. PubMed ID: 25622599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.